<DOC>
	<DOCNO>NCT03056599</DOCNO>
	<brief_summary>This feasibility study patient localize metastatic soft tissue sarcoma undergo surgery determine sarcoma situ responds injected microdoses anti-cancer therapeutic .</brief_summary>
	<brief_title>Precise Local Injection Anti-cancer Drugs Using Presage 's CIVO™ Device Soft Tissue Sarcoma</brief_title>
	<detailed_description>This single arm , pilot study design test feasibility use CIVO ( Comparative In Vivo Oncology ) system patient soft tissue sarcoma accessible percutaneous injection . Patients scheduled surgical biopsy tumor resection surgery inject one three day prior surgery use CIVO device . Minute volume ( 8.3 microliters ) saline ( negative control ) microdoses anti-cancer agent percutaneously inject columnar fashion 8 needle single enlarge solid tumor . Following patient 's biopsy surgery tumor resection surgery , inject portion small uninjected portion use determine situ drug response tumor . None data evaluation share patient use make clinical decision . Study clinicians access patient 's health record 1 year study monitor patient treatment response . Such information use help evaluate correlation clinical response tumor response assess via CIVO .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Antineoplastic Agents</mesh_term>
	<mesh_term>Interferon-gamma</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>18 year age . At least one soft tissue sarcoma tumor consider accessible percutaneous injection investigator least 3 cm long dimension . Prior surgical evaluation plan surgical biopsy surgery remove tumor inject . ECOG performance status 02 ( Karnofsky performance status &gt; 50 % ) ( Appendix B ) . Labs require enrollment ( prior microinjection ) : Absolute neutrophil count &gt; 1000/mm3 Platelet count &gt; 50,000/mm3 hematocrit &gt; 25 % Creatinine &lt; 3,0 mg/dl Total bilirubin &lt; 4,0 mg/dl Bilirubin &lt; 4,0 mg/dl , SGOT ≤ 1.5 time upper limit normal PT PTT ≤ 1.5 time upper limit normal Any therapy potentially immunosuppressive anticancer activity 4 week prior device microinjection . Subjects active fungal , viral , bacterial infection . Pregnant woman . Inability give inform consent . Current treatment anticoagulation warfarin lowmolecularweight heparin . Tumors near critical structure locate near brain spine . This judgement determine treat clinician .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>vivo drug sensitivity</keyword>
	<keyword>personalize medicine</keyword>
	<keyword>precision oncology</keyword>
	<keyword>vivo oncology</keyword>
	<keyword>soft tissue sarcoma</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>microinjection</keyword>
	<keyword>microdosing</keyword>
</DOC>